| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
24,810,000 |
| Market
Cap: |
4.62(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.0903 - $3.42 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Galera Therapeutics is a clinical stage biopharmaceutical company focused on developing and commercializing a pipeline of therapeutics that have the potential to transform radiotherapy in cancer. Co. utilizes its capabilities in superoxide dismutase mimetics to design drugs to reduce normal tissue toxicity from radiotherapy and to increase the anti-cancer efficacy of radiotherapy. Co.'s product candidate, avasopasem manganese, GC4419, is a selective small molecule dismutase mimetic that is developing for the reduction of severe oral mucositis. Co.'s another dismutase mimetic product candidate, GC4711, is to increase the anti-cancer efficacy of stereotactic body radiation therapy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
932,402 |
932,402 |
932,402 |
1,053,402 |
| Total Buy Value |
$166,417 |
$166,417 |
$166,417 |
$378,847 |
| Total People Bought |
1 |
1 |
1 |
4 |
| Total Buy Transactions |
6 |
6 |
6 |
9 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Schneid Yair |
10% Owner |
– – • |
2024-02-08 |
4 |
B |
$0.17 |
$25,650 |
D/D |
150,000 |
8,043,203 |
2.37 |
22% |
|
| Schneid Yair |
10% Owner |
– – • |
2024-02-07 |
4 |
B |
$0.17 |
$30,185 |
D/D |
175,000 |
7,893,203 |
2.37 |
22% |
|
| Schneid Yair |
10% Owner |
– – • |
2024-02-06 |
4 |
B |
$0.20 |
$5,025 |
D/D |
25,000 |
7,718,203 |
2.37 |
21% |
|
| Schneid Yair |
10% Owner |
– – • |
2024-02-05 |
4 |
B |
$0.18 |
$17,922 |
D/D |
97,402 |
7,693,203 |
2.37 |
24% |
|
| Schneid Yair |
10% Owner |
– – • |
2024-01-30 |
4 |
B |
$0.18 |
$60,635 |
D/D |
335,000 |
7,595,801 |
2.45 |
12% |
|
| Schneid Yair |
10% Owner |
– – • |
2024-01-29 |
4 |
B |
$0.18 |
$27,000 |
D/D |
150,000 |
7,260,801 |
2.37 |
15% |
|
| Schneid Yair |
10% Owner |
– – • |
2024-01-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
7,110,801 |
|
38% |
|
| Pearson Mark E. |
10% Owner |
– – • |
2023-10-31 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,280,000 |
|
123% |
|
| Bachleda Mark |
Chief Commercial Officer |
• – – |
2023-03-16 |
4 |
B |
$2.25 |
$24,717 |
D/D |
11,000 |
11,000 |
2.74 |
11% |
|
| Degnan Chris |
Chief Financial Officer |
• – – |
2023-03-13 |
4 |
B |
$1.96 |
$19,593 |
D/D |
10,000 |
10,000 |
2.74 |
45% |
|
| Sorensen Mel |
President and CEO |
• • – |
2023-03-10 |
4 |
B |
$1.68 |
$168,120 |
D/D |
100,000 |
332,044 |
2.81 |
65% |
|
| Beardsley Robert A |
Chief Operating Officer |
• – – |
2022-11-21 |
4 |
OE |
$1.07 |
$10,700 |
D/D |
10,000 |
108,191 |
|
- |
|
| Beardsley Robert A |
Chief Operating Officer |
• – – |
2022-09-12 |
4 |
OE |
$1.07 |
$10,700 |
D/D |
10,000 |
98,191 |
|
- |
|
| Alleva Lawrence M |
Director |
– • – |
2022-07-18 |
4 |
GD |
$0.00 |
$0 |
D/D |
4,000 |
2,325 |
|
- |
|
| West Linda |
Director |
– • – |
2021-12-17 |
4 |
B |
$2.74 |
$54,804 |
D/D |
20,000 |
60,000 |
2.39 |
-43% |
|
| Beardsley Robert A |
Chief Operating Officer |
• – – |
2021-12-17 |
4 |
OE |
$1.07 |
$21,400 |
D/D |
20,000 |
88,191 |
|
- |
|
| Holmlud Jon T |
Chief Medical Officer |
• – – |
2021-09-01 |
4 |
AS |
$8.47 |
$404,498 |
D/D |
(47,756) |
0 |
|
-59% |
|
| Holmlud Jon T |
Chief Medical Officer |
• – – |
2021-09-01 |
4 |
OE |
$2.43 |
$116,047 |
D/D |
47,756 |
47,756 |
|
- |
|
| West Linda |
Director |
– • – |
2021-06-15 |
4 |
B |
$9.13 |
$91,300 |
D/D |
10,000 |
40,000 |
2.39 |
-78% |
|
| West Linda |
Director |
– • – |
2021-06-02 |
4 |
B |
$8.65 |
$86,511 |
D/D |
10,000 |
30,000 |
2.39 |
-9% |
|
| Alleva Lawrence M |
Director |
– • – |
2021-06-01 |
4 |
B |
$8.59 |
$34,741 |
I/I |
4,045 |
4,045 |
2.1 |
-9% |
|
| West Linda |
Director |
– • – |
2021-06-01 |
4 |
B |
$8.64 |
$86,381 |
D/D |
10,000 |
20,000 |
2.39 |
-9% |
|
| West Linda |
Director |
– • – |
2021-05-28 |
4 |
B |
$8.64 |
$86,410 |
D/D |
10,000 |
10,000 |
2.39 |
-9% |
|
| Sorensen Mel |
President and CEO |
• • – |
2021-03-26 |
4 |
OE |
$1.07 |
$235,492 |
D/D |
217,015 |
232,044 |
|
- |
|
| Novo A/s |
10% Owner |
– – • |
2021-02-18 |
4 |
S |
$10.58 |
$5,290,000 |
D/D |
(500,000) |
2,459,021 |
|
11% |
|
89 Records found
|
|
Page 1 of 4 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.02 (10.31%) 
